Sanofi (SNY) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Sanofi’s Dupixent, the first biologic medicine for COPD, has been approved in China, offering a new treatment for patients with the most prevalent chronic respiratory disease in the country. This approval is a significant development in the public health landscape, aligning with the Healthy China 2030 plan to enhance the quality of life for those affected by COPD. Dupixent has demonstrated considerable efficacy in reducing exacerbations, improving lung function, and enhancing health-related quality of life in phase 3 studies.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
